Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,359 stopped studies mapped to Non-Hodgkin Lymphoma and descendants · 89% state a reason
Over the 1,359 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01464034 | A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in… | Phase 1 / Phase 2 | terminated | Nov 3, 2011 | Criterium, Inc. | Lack of enrollment | Enrollment / accrual |
| NCT02793583 | Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without…(UNITY-NHL) | Phase 2 / Phase 3 | terminated | Jun 8, 2016 | TG Therapeutics, Inc. | Strategic/Business Decision | Sponsor / business decision |
| NCT03207256 | Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in… | Phase 2 | terminated | Jul 2, 2017 | TG Therapeutics, Inc. | Strategic/Business Decision | Sponsor / business decision |
| NCT03768310 | CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic… | Phase 1 | withdrawn | Dec 7, 2018 | Baylor College of Medicine | We decided to move on to another product and as a result will not be moving forward with this study. | Other (stated, no rule matched) |
| NCT00464178 | A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory… | Phase 2 | terminated | Apr 23, 2007 | Hackensack Meridian Health | The study was closed early due to poor accrual | Enrollment / accrual |
| NCT01241786 | Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for…(VZCLLPI0146) | Phase 2 | terminated | Nov 16, 2010 | Hackensack Meridian Health | The study was closed early due to poor accrual | Enrollment / accrual |
| NCT04796922 | To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in… | Phase 3 | withdrawn | Mar 15, 2021 | Incyte Corporation | This study was withdrawn due to a business decision. | Sponsor / business decision |
| NCT01555281 | Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma | Phase 1 / Phase 2 | terminated | Mar 15, 2012 | Swiss Cancer Institute | In connection with the restructuring of SAKK, older ongoing studies were analyzed to determine… | Other (stated, no rule matched) |
| NCT04802031 | Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma | Phase 2 | withdrawn | Mar 17, 2021 | Thomas Martin, MD | Low accrual | Enrollment / accrual |
| NCT04467281 | A Study of PET/CT Scans With the Radioactive Tracer 89Zr-DFO-Daratumumab in People With… | Phase 2 | withdrawn | Jul 13, 2020 | Memorial Sloan Kettering Cancer Center | PI left institution and study is being transferred. | Investigator |
| NCT03841565 | Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple… | Phase 2 | withdrawn | Feb 15, 2019 | Academic and Community Cancer Research United | There are no patients enrolled on this study and all efforts are being discontinued. | Enrollment / accrual |
| NCT04836832 | Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin… | Phase 1 | withdrawn | Apr 8, 2021 | Narendranath Epperla | PI decision | Other (stated, no rule matched) |
| NCT02374424 | Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL Patients(GIOTTO) | Phase 2 | terminated | Feb 27, 2015 | Fondazione Italiana Linfomi - ETS | Interim analysis planned as per protocol didn't provide positive outcome therefore enrollment was… | Efficacy / futility |
| NCT03660072 | Postmarketing Study of Empliciti in Korean Patients With Multiple Myeloma | — | withdrawn | Sep 6, 2018 | Bristol-Myers Squibb | Business objectives have changed | Sponsor / business decision |
| NCT03752541 | Efficacy and Safety Evaluation of BCMA-UCART | N/A | suspended | Nov 26, 2018 | Bioray Laboratories | decided by the sponsor | Other (stated, no rule matched) |
| NCT04844086 | RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies | Phase 1 | terminated | Apr 14, 2021 | Eden BioCell Ltd. | CAR-T manufacturing technology can not meet the dose requirement for clinical patients. | Drug supply |
| NCT03492268 | Safety and Efficacy Evaluation of BCMA-CART for Treating Multiple Myeloma | N/A | withdrawn | Apr 10, 2018 | Bioray Laboratories | Due to CART processing facility construction | Other (stated, no rule matched) |
| NCT01744912 | Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies | Phase 1 | terminated | Dec 7, 2012 | TG Therapeutics, Inc. | Sponsor's decision | Sponsor / business decision |
| NCT03256045 | Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory… | Phase 2 | terminated | Aug 21, 2017 | University of Washington | Terminated due to loss of funding and former PI left the institution | Investigator |
| NCT04535102 | POLA+BR for Relapsed or Refractory DLBCL | Phase 2 | withdrawn | Sep 1, 2020 | University of Colorado, Denver | Lack of sufficient patient population | Other (stated, no rule matched) |
| NCT03303950 | Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis | Phase 2 | terminated | Oct 6, 2017 | University of Utah | Slow accrual | Enrollment / accrual |
| NCT05170789 | Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma(ESdRRMM) | Phase 2 | withdrawn | Dec 28, 2021 | Tulane University School of Medicine | The study collaborator -Karyopharm- is not doing Myeloma studies funding, so they let the study… | Funding |
| NCT05183139 | A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and…(US MM-7) | Phase 4 | withdrawn | Jan 10, 2022 | Takeda | Business decision (no enrollment) | Enrollment / accrual |
| NCT02043587 | Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic… | Phase 2 | terminated | Jan 23, 2014 | University of California, San Diego | Original investigator for the trial has left | Investigator |
| NCT04849715 | A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab…(CITADEL-310) | Phase 3 | withdrawn | Apr 19, 2021 | Incyte Corporation | business decision; no enrolled patients | Enrollment / accrual |
| NCT04361851 | Study of Dara-Pembro for Multiple Myeloma Patients | Phase 2 | withdrawn | Apr 24, 2020 | Wake Forest University Health Sciences | Low enrollment due to competing studies | Enrollment / accrual |
| NCT04230031 | Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma | Phase 2 | withdrawn | Jan 18, 2020 | Wake Forest University Health Sciences | Difficult enrollment due to changes in standard of care | Enrollment / accrual |
| NCT03850522 | PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma | Phase 2 | terminated | Feb 21, 2019 | Lene Meldgaard Knudsen | Insufficient recruitment within planned enrolmentperiod. | Enrollment / accrual |
| NCT04155840 | Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic… | Phase 2 | terminated | Nov 7, 2019 | University of Washington | Terminated due to low accrual | Enrollment / accrual |
| NCT03713320 | SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With…(SOLAR) | Phase 2 | terminated | Oct 19, 2018 | miRagen Therapeutics, Inc. | The study was terminated early for business reasons, and not due to concerns regarding safety or… | Safety / toxicity |
| NCT02420795 | Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's… | Phase 1 / Phase 2 | terminated | Apr 20, 2015 | M.D. Anderson Cancer Center | Per PI Request | Other (stated, no rule matched) |
| NCT03886649 | Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell… | Phase 1 | terminated | Mar 22, 2019 | Swiss Cancer Institute | Insufficient Funding | Funding |
| NCT01187810 | Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL | Phase 1 | terminated | Aug 24, 2010 | South Plains Oncology Consortium | drug supply | Drug supply |
| NCT03104270 | Combination Study for High Risk Multiple Myeloma Patients | Phase 2 | terminated | Apr 7, 2017 | Oncotherapeutics | The study was terminated early by Funding Sponsor due to low enrollment. | Enrollment / accrual |
| NCT04974996 | A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of…(LOTIS-8) | Phase 1 | withdrawn | Jul 23, 2021 | ADC Therapeutics S.A. | Decision to not proceed with study. | Other (stated, no rule matched) |
| NCT04115956 | A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With… | Phase 1 | terminated | Oct 4, 2019 | Oncopeptides AB | The sponsor decided to terminate the study following an FDA request of a partial clinical hold. | Sponsor / business decision |
| NCT02356458 | Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma | Phase 1 / Phase 2 | terminated | Feb 5, 2015 | Swiss Cancer Institute | SAKK Board decision of 14th November 2020 due to financial reasons. | Funding |
| NCT02519270 | Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects(NHL) | Phase 1 | terminated | Aug 10, 2015 | Spectrum Pharmaceuticals, Inc | Strategic Reasons | Sponsor / business decision |
| NCT02847949 | A Study of IGN002 for Refractory NHL | Phase 1 | withdrawn | Jul 28, 2016 | Spectrum Pharmaceuticals, Inc | Strategic Reasons | Sponsor / business decision |
| NCT04990778 | Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell… | Phase 2 | withdrawn | Aug 4, 2021 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT04209621 | Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | terminated | Dec 24, 2019 | National Heart, Lung, and Blood Institute (NHLBI) | Due to unexpected sudden death on study. | Other (stated, no rule matched) |
| NCT02998047 | A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma | Phase 1 | terminated | Dec 20, 2016 | Actinium Pharmaceuticals | Poor recruitment | Enrollment / accrual |
| NCT01685606 | Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight…(273) | Phase 2 | terminated | Sep 14, 2012 | Brown University | Lack of accrual and low efficacy | Efficacy / futility |
| NCT04456023 | Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse… | Phase 2 | withdrawn | Jul 2, 2020 | Novartis Pharmaceuticals | This study was cancelled before enrolling any patients for business related reasons. | Enrollment / accrual |
| NCT02954406 | A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine,… | Phase 1 | terminated | Nov 3, 2016 | Millennium Pharmaceuticals, Inc. | Business decision, insufficient enrollment, no safety or efficacy concerns. | Safety / toxicity |
| NCT04160195 | T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for… | Phase 1 | terminated | Nov 12, 2019 | National Cancer Institute (NCI) | The original principal investigator left the National Institutes of Health (NCI) and the decision… | Investigator |
| NCT04697290 | CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients. | Early Phase 1 | suspended | Jan 6, 2021 | Beijing Tsinghua Chang Gung Hospital | Plan adjustment | Other (stated, no rule matched) |
| NCT00792506 | Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma | Phase 2 | terminated | Nov 18, 2008 | Italfarmaco | The study was prematurely discontinued for lack of recruitement. | Enrollment / accrual |
| NCT03875495 | A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse… | Phase 1 / Phase 2 | terminated | Mar 14, 2019 | Genenta Science | Failure to recruit patients | Enrollment / accrual |
| NCT04150692 | Escalation of Daratumumab Frequency Following Biochemical Progression in… | Phase 2 | withdrawn | Nov 5, 2019 | Washington University School of Medicine | Investigator decision | Investigator |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 1, 2022source: clinicaltrials